VMVincent A. Miller

Vincent A. Miller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vincent A. Miller has a total of 116 co-authors. Here are the top co-authors by number of shared publications:

  • Mark G. Kris

    Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    10 shared publications
  • Robert T. Heelan

    Departments of Radiology, and Weill Medical College of Cornell University, New York City, New York

    8 shared publications
  • William Pao

    Authors' Affiliations: 1Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts; 2Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, New York; and 3Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

    8 shared publications
  • Lee M. Krug

    Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology

    6 shared publications
  • Barbara Pizzo

    Department of Nursing, Memorial Sloan-Kettering Cancer Center and the Weill Medical College of Cornell University, New York, New York

    5 shared publications
  • Gregory J. Riely

    Authors' Affiliations: 1Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, 2Molecular Diagnostics Service, Department of Pathology, 3Department of Epidemiology and Biostatistics, and 4Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York

    5 shared publications

Latest Publications

  • Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, demographics, and molecular markers.

    by Vassiliki Papadimitrakopoulou, Mary Redman, David R. Gandara, Fred R. Hirsch, Philip C. Mack, Hossein Borghaei, Corey J. Langer, Jeffrey A. Engelman, Martin J. Edelman, Kathy S. Albain, et al.

    9088 Background: Lung-MAP (S1400), coordinated by SWOG on behalf of NCTN, is a first-in-kind master “umbrella” protocol in partnership between government, academia, patient advocacy organizations, and industry, designed to simultaneously and independently test multiple biomarker-driven therapies for patients (pts) with chemo-refractory squamous cell lung cancer (SCCA). Methods: Lung-MAP currently includes 3 biomarker-driven sub-studies and one non-match study for pts not eligible to enroll onto a biomarker-driven sub-study. If genomic screening identifies a molecular match, pts are assigned to: S1400B evaluating taselisib, a PI3K inhibitor, S1400C evaluating palbociclib, a CDK 4/6 inhibitor and, S1400D evaluating AZD4547, an FGFR inhibitor. The recently activated non –match sub-study S1400I tests nivolumab + ipilimumab vs. nivolumab alone (S1400E evaluating rilotumumab an HGF monoclonal antibody + erlotinib closed 11/26/2014 and S1400A evaluating MEDI4736 in non-match ptsclosed 12/18/2015). Results: From June 16, 2014 to January 20, 2016, 418 sites opened, 525 pts registered to the screening component of the trial, and 210 pts registered to a sub-study: 116 to S1400A, 17 to S1400B, 36 to S1400C, 24 to S1400D, 9 to S1400E and 6 to S1400I. Demographics: Median age 67(range 35-92); male 68%; ECOG PS 0-1 80%, PS 2 16%; Caucasian 85%, Black 8%, other 8%; never/former/current smokers 3%/60%/33%. Of 507 pts genomically screened, 450 (89%) were successful . Table 1 displays biomarker prevalence and overlap; 60% of pts had no match and 0.2% had all 3. Conclusions: This novel master protocol designed to challenge current drug development paradigms and expedite drug registration, is demonstrating feasibility of genomic screening and confirms anticipated prevalence of targeted alterations in SCCA. Support: Supported in part by NIH/NCI (CA180888, CA180819, CA180820, CA180821), and by Amgen, AstraZeneca, Bristol-Myers Squibb Company, Genentech and Pfizer through the Foundation for the National Institutes of Health, in partnership with Friends of Cancer Research. Clinical trial information: NCT02154490.

  • New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer

    by Geoffrey R. Oxnard, Maria E. Arcila, Juliann Chmielecki, Marc Ladanyi, Vincent A. Miller, William Pao

    The management of non–small cell lung carcinoma (NSCLC) has been transformed by the observation that lung adenocarcinomas harboring mutations in epidermal growth factor receptor (EGFR) are uniquely sensitive to EGFR tyrosine kinase inhibitors (TKI). In these patients, acquired resistance to EGFR-TKI develops after a median of 10 to 14 months, at which time the current standard practice is to switch to conventional cytotoxic chemotherapy. Several possible mechanisms for acquired resistance have been identified, the most common being the development of an EGFR T790M gatekeeper mutation in more than 50% of cases. In this review, we discuss recent advances in the understanding of acquired TKI resistance in EGFR-mutant lung cancer and review therapeutic progress with second generation TKIs and combinations of targeted therapies. Clin Cancer Res; 17(17); 5530–7. ©2011 AACR.


  • Top Cited Papers

    Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

    by Geoffrey R. Oxnard, Maria E. Arcila, Camelia S. Sima, Gregory J. Riely, Juliann Chmielecki, Mark G. Kris, William Pao, Marc Ladanyi, Vincent A. Miller

    Purpose: Patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI) after a median of 10 to 16 months. In half of these cases, a second EGFR mutation, T790M, underlies acquired resistance. We undertook this study to examine the clinical course of patients harboring the T790M mutation following progression on TKI. Experimental Design: EGFR-mutant lung cancer patients with acquired resistance to EGFR TKIs were identified as part of a prospective rebiopsy protocol in which postprogression tumor specimens were collected for molecular analysis. Postprogression survival and characteristics of disease progression were compared in patients with and without T790M. Results: We identified T790M in the initial rebiopsy specimens from 58 of 93 patients (62%, 95% CI: 52–72). T790M was more common in biopsies of lung/pleura tissue and lymph nodes than in more distant sites (P = 0.014). Median postprogression survival was 16 months (interquartile range = 9–29 months); patients with T790M had a significantly longer postprogression survival (P = 0.036). Patients without T790M more often progressed in a previously uninvolved organ system (P = 0.014) and exhibited a poorer performance status at time of progression (P = 0.007). Conclusions: Among patients with acquired resistance to EGFR TKIs, the presence of T790M defines a clinical subset with a relatively favorable prognosis and more indolent progression. Knowledge of T790M status is therefore important both for the clinical care of these patients and for the optimal design and interpretation of clinical trials in this setting. Clin Cancer Res; 17(6); 1616–22. ©2010 AACR.


  • Open Access

    Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer

    by Katharine A. Price, Christopher G. Azzoli, Lee M. Krug, Maria C. Pietanza, Naiyer A. Rizvi, William Pao, Mark G. Kris, Gregory J. Riely, Robert T. Heelan, Maria E. Arcila, et al.


  • Top Cited Papers

    Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

    by David Jackman, William Pao, Gregory J. Riely, Jeffrey A. Engelman, Mark G. Kris, Pasi A. Jänne, Thomas Lynch, Bruce E. Johnson, Vincent A. Miller

    Ten percent of North American patients with non–small-cell lung cancer have tumors with somatic mutations in the gene for the epidermal growth factor receptor (EGFR). Approximately 70% of patients whose lung cancers harbor somatic mutations in exons encoding the tyrosine kinase domain of EGFR experience significant tumor regressions when treated with the EGFR tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib. However, the overwhelming majority of these patients inevitably acquire resistance to either drug. Currently, the clinical definition of such secondary or acquired resistance is not clear. We propose the following criteria be used to define more precisely acquired resistance to EGFR TKIs. All patients should have the following criteria: previous treatment with a single-agent EGFR TKI (eg, gefitinib or erlotinib); either or both of the following: a tumor that harbors an EGFR mutation known to be associated with drug sensitivity or objective clinical benefit from treatment with an EGFR TKI; systemic progression of disease (Response Evaluation Criteria in Solid Tumors [RECIST] or WHO) while on continuous treatment with gefitinib or erlotinib within the last 30 days; and no intervening systemic therapy between cessation of gefitinib or erlotinib and initiation of new therapy. The relatively simple definition proposed here will lead to a more uniform approach to investigating the problem of acquired resistance to EGFR TKIs in this unique patient population. These guidelines should minimize reporting of false-positive and false-negative activity in these clinical trials and would facilitate the identification of agents that truly overcome acquired resistance to gefitinib and erlotinib.


  • Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib

    by Vincent A. Miller, Gregory J. Riely, Maureen F. Zakowski, Allan R. Li, Jyoti D. Patel, Robert T. Heelan, Mark G. Kris, Alan B. Sandler, David P. Carbone, Anne Tsao, et al.

    Purpose: We conducted this phase II trial to determine the efficacy of erlotinib in patients with bronchioloalveolar carcinoma (BAC) and adenocarcinoma, BAC subtype, and to determine molecular characteristics associated with response. Patients and Methods: Patients (n = 101) with BAC (n = 12) or adenocarcinoma, BAC subtype (n = 89), were enrolled. All patients received erlotinib 150 mg daily. Epidermal growth factor receptor (EGFR) mutation, EGFR copy number, EGFR immunohistochemistry (IHC), and KRAS mutation status were analyzed in available tumors. The primary end point was response rate (RR). Results: Overall RR was 22% (95% CI, 14% to 31%). In patients with pure BAC, the RR and median survival were 20% and 4 months, as compared with 23% and 19 months in those with adenocarcinoma, BAC subtype. No patient (zero of 18; 95% CI, 0% to 19%) whose tumor harbored a KRAS mutation responded to erlotinib. Patients with EGFR mutations had an 83% RR (15 of 18; 95% CI, 65% to 94%) and 23-month median OS. On univariate analysis, EGFR mutation and copy number were associated with RR and PFS. EGFR IHC was not associated with RR or progression-free survival (PFS). After multivariate analysis, only EGFR mutation was associated with RR and PFS. No molecular factors were associated with overall survival. Conclusion: Erlotinib is active in BAC and adenocarcinoma, mixed subtype, BAC. Testing for EGFR and KRAS mutations can predict RR and PFS after treatment with erlotinib in this histologically enriched subset of patients with non–small-cell lung cancer (NSCLC). These data suggest that histologic subtype and molecular characteristics should be reported in clinical trials in NSCLC using EGFR-directed therapy.


  • Open Access

    Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall‐cell lung cancer

    by Daniel T. Milton, Gregory J. Riely, Christopher G. Azzoli, Jorge E. Gomez, Robert T. Heelan, Mark G. Kris, Lee M. Krug, William Pao, Barbara Pizzo, Naiyer A. Rizvi, et al.

    BACKGROUND.: Preclinical studies have demonstrated that the inhibition of the PI3K/Akt/mTOR pathway restores gefitinib sensitivity in resistant cancer cell lines. A phase 1 study was conducted of the combination of everolimus, an mTOR inhibitor, and gefitinib to determine a daily dose of everolimus with gefitinib in patients with advanced nonsmall‐cell lung cancer (NSCLC).METHODS.: Oral everolimus and gefitinib were both administered daily to patients with progressive NSCLC. Patients were enrolled in 3‐patient cohorts at everolimus dose levels of 5 and 10 mg daily. All patients received gefitinib 250 mg daily.RESULTS.: Ten patients were enrolled. The maximum tolerated dose of everolimus was 5 mg when administered daily with gefitinib 250 mg. Two patients who were treated at the 10 mg dose level of everolimus experienced dose‐limiting toxicity, including grade 5 hypotension and grade 3 stomatitis. Pharmacokinetic studies demonstrated no consistent, significant interaction on the tmax, Cmax, and AUC0‐8h of either agent. Two partial radiographic responses were identified among the 8 response‐evaluable patients.CONCLUSIONS.: For further study, everolimus at a dose of 5 mg daily in combination with daily gefitinib 250 mg is recommended. The 2 radiographic responses identified are encouraging. A phase 2 trial in patients with NSCLC is under way. Cancer 2007. © 2007 American Cancer Society.


  • Open Access

    A phase I/II study of weekly high‐dose erlotinib in previously treated patients with nonsmall cell lung cancer

    by Daniel T. Milton, Christopher G. Azzoli, Robert T. Heelan, Ennapadam Venkatraman, Jorge E. Gomez, Mark G. Kris, Lee M. Krug, William Pao, Naiyer A. Rizvi, Megan Dunne, et al.

    BACKGROUND.: Preclinical studies have suggested that erlotinib at high doses may inhibit additional sites downstream of the epidermal growth factor receptor (EGFR), resulting in greater antitumor efficacy. The objective of this study was to determine the tolerability and efficacy of high‐dose erlotinib administered on a weekly schedule to patients with advanced nonsmall cell lung cancer (NSCLC).METHODS.: The authors conducted a Phase I/II trial of weekly erlotinib in patients with progressive NSCLC who had received previous chemotherapy. In the Phase I portion, patients were enrolled in 3‐patient cohorts at erlotinib dose levels of 1200 mg, 1600 mg, and 2000 mg once weekly. The Phase II portion was designed to determine the major objective response rate of the dose identified in the Phase I portion of the trial.RESULTS.: Twenty‐seven patients were enrolled. No dose‐limiting toxicity was observed. Grade 1 and 2 rash and diarrhea were the principle toxicities, and each occurred in 92% of patients. Among 21 patients who were treated at the Phase II dose of 2000 mg weekly, a single objective response was identified, yielding a response rate of 5% (95% confidence interval, 0.2–22%). For this cohort, the median survival was 9.5 months. The sole radiographic response occurred in a patient whose pretreatment tumor specimen harbored an EGFR exon 19 deletion.CONCLUSIONS.: Erlotinib at a dose of 2000 mg administered weekly was tolerated well by these patients with advanced NSCLC. The 5% objective response rate did not reach the stated objective at the interim efficacy analysis, prompting the closure of the study. Cancer 2006. © 2006 American Cancer Society.